Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 29, 2015 1:50 PM ET


Company Overview of Aptalis Holdings Inc.

Company Overview

Aptalis Holdings Inc. develops, manufactures, licenses, and markets therapies for cystic fibrosis (CF) and gastrointestinal disorders. Its principal products include ZENPEP and ULTRESA for the treatment of exocrine pancreatic insufficiency (EPI) due to CF or other conditions; VIOKACE for the treatment of EPI due to chronic pancreatitis or pancreatectomy in adults; PANZYTRAT for the treatment of EPI and pancreatic enzyme deficiency; and RECTIV for the treatment of moderate to severe pain associated with chronic anal fissure. The company’s products also comprise CARAFATE for the short-term treatment of active duodenal ulcers; PYLERA for the treatment of patients with helicobacter pylori, infec...

100 Somerset Corporate Boulevard

Suite 2000

Bridgewater, NJ 08807

United States

Founded in 2008

961 Employees





Key Executives for Aptalis Holdings Inc.

President of Aptalis Pharma
Age: 49
Senior Vice President, General Counsel and Corporate Secretary
Age: 60
Compensation as of Fiscal Year 2015.

Aptalis Holdings Inc. Key Developments

Aptalis Holdings Inc. Presents at BIO International Convention, Jun-25-2014 11:00 AM

Aptalis Holdings Inc. Presents at BIO International Convention, Jun-25-2014 11:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Forest Laboratories To Reportedly Acquire Aptalis From TPG Capital

Forest Laboratories Inc. (NYSE:FRX) is nearing an agreement to acquire Aptalis Holdings Inc. from TPG Capital, L.P. for about $3 billion, a person familiar with the matter said. A deal announcement could come as early as January 8, 2014, the person said, cautioning that negotiations were still being finalized. The source asked not to be identified because the talks are confidential. According to Reuters, Forest and Aptalis did not immediately respond to requests for comment. TPG declined to comment.

Aptalis Holdings Seeks Acquisitions

Aptalis Holdings Inc. has made an offering of $500 million. A part of the proceeds will be used for future acquisitions.

Similar Private Companies By Industry

Company Name Region
Deseret Laboratories, Inc. United States
Serene Oncology, LLC United States
Endo Pharmaceuticals Colorado LLC United States
A-FAM LLC Inc. United States
Memcine Pharmaceuticals Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Aptalis Holdings Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at